Navigation Links
3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
Date:3/24/2009

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

Patients with locally advanced larynx and hypopharynx cancer are treated frequently with PF chemotherapy followed by radiation as an alternative to surgical removal of the larynx. Recent trials have suggested that adding docetaxel to PF might further improve patient outcomes.

To test this possibility, Gilles Calais, M.D., of the Centre Hospitalier Rgional et Universitaire de Tours in France, and colleagues enrolled 213 patients with advanced larynx and hypopharynx cancer in a randomized controlled trial. Patients received induction chemotherapy with either TPF or PF. Those who responded to chemotherapy underwent subsequent radiation therapy, while those who did not respond were treated with surgery.

With a median follow-up time of 3 years, the estimated larynx preservation rate was 70.3 percent in the TPF-treated patients and 57.5 percent in the PF-treated patients. Overall, 80.0 percent of patients in the TPF group responded to therapy, compared with 59.2 percent in the PF group. Patients treated with TPF had more severe infections than those treated with PF.

The authors conclude that the treatment regimen with docetaxel was superior for patients with locally advanced cancers of the larynx and hypopharynx and that more of these patients could avoid total laryngectomy. However, they caution that "Because we proposed treatment to a select population of patients with only larynx and hypopharynx cancer and this trial was especially designed for organ preservation, we cannot generalize the findings to all locally advanced head and neck cancers."


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
2. 3-drug combination extremely promising as first-line therapy for multiple myeloma
3. Scientists trial device to treat chemotherapy-related nausea
4. Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
5. Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy
6. How chemotherapy drugs block blood vessel growth, slow cancer spread
7. UNC study supports role of circadian clock in response to chemotherapy
8. Gene Governs Response to Leukemia Chemotherapy
9. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
10. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
11. Studies show novel device may enhance chemotherapy treatment in brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for ... and mood optimization products to the store is just one more way Shamangelic ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... St. Petersburg, Fla. (PRWEB) , ... April 29, ... ... All Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia ... 3,000 babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... the development of oral drug delivery systems, announced today that ... presented by Joseph Gunnar & Co. LLC, taking ... . Nadav Kidron , CEO of Oramed, will ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
Breaking Medicine Technology: